(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
3 September 2009 (03.09.2009)

PCT

(10) International Publication Number
WO 2009/107850 A3

(51) International Patent Classification:
C07D 471/04 (2006.01) *A61K 31/4355* (2006.01)
C07D 498/04 (2006.01) *A61K 31/4365* (2006.01)
C07D 513/04 (2006.01) *A61K 31/437* (2006.01)
A61P 35/00 (2006.01)

(21) International Application Number:
PCT/JP2009/054007

(22) International Filing Date:
25 February 2009 (25.02.2009)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
2008-045134 26 February 2008 (26.02.2008) JP
2008-256755 1 October 2008 (01.10.2008) JP

(71) Applicant *(for all designated States except US)*: **TAKEDA PHARMACEUTICAL COMPANY LIMITED** [JP/JP]; 1-1, Doshomachi 4-chome, Chuo-ku, Osaka-shi, Osaka, 5410045 (JP).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: **FUJII, Nobuhiro** [JP/JP]; c/o TAKEDA PHARMACEUTICAL COMPANY LIMITED, 17-85, Jusohonmachi 2-chome, Yodogawa-ku, Osaka-shi, Osaka, 5328686 (JP). **OGURO, Yuya** [JP/JP]; c/o TAKEDA PHARMACEUTICAL COMPANY LIMITED, 10, Wadai, Tsukuba-shi, Ibaraki, 3004293 (JP). **SASAKI, Satoshi** [JP/JP]; c/o TAKEDA PHARMACEUTICAL COMPANY LIMITED, 10, Wadai, Tsukuba-shi, Ibaraki, 3004293 (JP). **KONDO, Shigeru** [—/JP]; c/o TAKEDA PHARMACEUTICAL COMPANY LIMITED, 17-85, Jusohonmachi 2-chome, Yodogawa-ku, Osaka-shi, Osaka, 5328686 (JP).

(74) Agent: **TAKASHIMA, Hajime**; Meiji Yasuda Seimei Osaka Midosuji Bldg., 1-1, Fushimimachi 4-chome, Chuo-ku, Osaka-shi, Osaka 5410044 (JP).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

[Continued on next page]

(54) Title: FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF



(I)

(57) Abstract: The present invention provides a compound having a superior Smo inhibitory activity and lower toxicity, which is sufficiently satisfactory as a pharmaceutical product.The present invention provides a compound represented by the formula (I) wherein ring A is 5- to 7-membered ring optionally having substituent(s), where substituents are optionally bonded to each other to form a ring; X is O, S or NR^1 (R^1 is a hydrogen atom or a hydrocarbon group optionally having substituent(s)); R^2 is carbamoyl optionally having substituent(s); and R^3 is hydroxy optionally having substituent(s), or a salt thereof.

WO 2009/107850 A3

— *with sequence listing part of description (Rule 5.2(a))*

(88) Date of publication of the international search report:
28 January 2010